Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.

肺癌是我国及世界范围内发病率和死亡率最高的恶性肿瘤之一，非小细胞肺癌（NSCLC）约占肺癌的 85%，1/3 的患者在确诊时已为局部晚期 NSCLC，5 年生存率仅 13% ~ 16%。其中，N2 期肺癌患者预后更差，手术切除后 3 年生存率仅 9% ...

The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...

Lung cancer is one of the most common and serious types of cancer - and spotting the early signs could save your life.

John Ryan, a U.S. Navy veteran, beat cancer through nearly a decade of experimental immunotherapy treatment. The vet shared ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Bristol Myers Squibb (BMS) has shared positive overall survival (OS) results from a late-stage study of its Opdivo (nivolumab) combination in non-small cell lung cancer (NSCLC).

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...